Douglas Lane & Associates LLC Sells 1,808 Shares of Gilead Sciences, Inc. (GILD)

Douglas Lane & Associates LLC trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,920 shares of the biopharmaceutical company’s stock after selling 1,808 shares during the quarter. Douglas Lane & Associates LLC’s holdings in Gilead Sciences were worth $683,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Gilead Sciences by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 97,167,329 shares of the biopharmaceutical company’s stock valued at $7,502,290,000 after purchasing an additional 1,071,619 shares in the last quarter. Vanguard Group Inc increased its holdings in shares of Gilead Sciences by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 97,167,329 shares of the biopharmaceutical company’s stock valued at $7,502,290,000 after purchasing an additional 1,071,619 shares in the last quarter. Capital Research Global Investors increased its holdings in shares of Gilead Sciences by 22.5% during the 3rd quarter. Capital Research Global Investors now owns 69,854,968 shares of the biopharmaceutical company’s stock valued at $5,393,502,000 after purchasing an additional 12,818,301 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Gilead Sciences by 199,789.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock valued at $2,420,587,000 after purchasing an additional 31,335,030 shares in the last quarter. Finally, Dodge & Cox increased its holdings in shares of Gilead Sciences by 1.2% during the 3rd quarter. Dodge & Cox now owns 16,450,181 shares of the biopharmaceutical company’s stock valued at $1,270,118,000 after purchasing an additional 190,370 shares in the last quarter. 78.01% of the stock is owned by hedge funds and other institutional investors.

Shares of GILD opened at $69.18 on Friday. Gilead Sciences, Inc. has a 52-week low of $60.32 and a 52-week high of $89.54. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.37 and a current ratio of 3.45. The firm has a market cap of $89.49 billion, a price-to-earnings ratio of 10.78, a price-to-earnings-growth ratio of -2.39 and a beta of 1.06.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.63 by $0.21. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. The company had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.44 billion. During the same quarter in the previous year, the company posted $2.27 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 6.44 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, December 28th. Shareholders of record on Friday, December 14th were paid a dividend of $0.57 per share. The ex-dividend date was Thursday, December 13th. This represents a $2.28 annualized dividend and a yield of 3.30%. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.

Several equities analysts have recently weighed in on GILD shares. Zacks Investment Research lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 25th. ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Friday, September 28th. BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Saturday, September 29th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a report on Monday, October 1st. They issued an “overweight” rating and a $87.00 price target for the company. Finally, Piper Jaffray Companies lowered shares of Gilead Sciences from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $85.00 to $75.00 in a report on Friday, October 26th. Ten analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and an average target price of $88.39.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $69.55, for a total transaction of $3,477,500.00. Following the sale, the director now owns 3,067,762 shares of the company’s stock, valued at approximately $213,362,847.10. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 1.16% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://transcriptdaily.com/2019/01/20/douglas-lane-associates-llc-sells-1808-shares-of-gilead-sciences-inc-gild.html.

About Gilead Sciences

Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Story: Analyst Ratings Trading

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply